23rd Jan 2019 16:31
Motif Bio plc
("Motif Bio" or the "Company")
Exercise of Warrants
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from warrant holders to exercise warrants representing 717,384 ordinary shares of 1p each ("Ordinary Shares") in the Company for total consideration of £152,626.80. The exercise price of warrants representing 642,384 Ordinary Shares was 20p per warrant. The exercise price of warrants representing 75,000 Ordinary Shares was 32.2 p per warrant.
Application has been made for the 717,384 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 29 January 2019. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 297,377,627 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
For further information please contact:
Motif Bio plc | |
Graham Lumsden (Chief Executive Officer) | |
Peel Hunt LLP (NOMAD & BROKER) | + 44 (0)20 7418 8900 |
Dr Christopher Golden | |
Oliver Jackson | |
Northland Capital Partners Limited (BROKER) | +44 (0)20 3861 6625 |
David Hignell/Vadim Alexandre/Rob Rees | |
Walbrook PR Ltd. (UK FINANCIAL PR & IR) | +44 (0)20 7933 8780 |
Paul McManus/Helen Cresswell/Lianne Cawthorne | |
MC Services AG (EUROPEAN IR) | +49 (0) 89 210 2280 |
Raimund Gabriel | |
Solebury Trout (U.S. IR) | + 1 (646) 378-2963 |
Meggie Purcell | |
Russo Partners (U.S. PR) | +1 (858) 717-2310 or +1 (212) 845 4272 |
David Schull | |
Travis Kruse, Ph.D. |
Related Shares:
MTFB.L